Overexpression of the epidermal growth factor receptor (EGFR) gene and dysregulation of EGFR signaling are observed in various cancer cells, and EGFR is a validated target for cancer therapy. In the present study, we report on the generation of two rat anti-EGFR antibodies (clones 2C2D3 and 4H7F4) by using the rat lymph node method. Flow cytometric analysis and immunofluorescence showed that both antibodies specifically bound to EGFR on the surface of cancer cells. Competitive analysis demonstrated that the epitope of each antibody had no overlap with that of the therapeutic anti-EGFR antibody cetuximab. These results suggest that 2C2D3 and 4H7F4 are potentially useful in EGFR-targeted cancer therapy.
Get full access to this article
View all access options for this article.
References
1.
FergusonKM, BergerMB, MendrolaJM, ChoHS, LeahyDJ, and LemmonMA: EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell, 2003; 11:507–517.
2.
YardenY, and SliwkowskiMX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol, 2001; 2:127–137.
3.
NormannoN, De LucaA, BiancoC, StrizziL, MancinoM, MaielloMR, CarotenutoA, De FeoG, CaponigroF, and SalomonDS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 2006; 366:2–16.
4.
MartinelliE, De PalmaR, OrdituraM, De VitaF, and CiardielloF: Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol, 2009; 158:1–9.
VlacichG, and CoffeyRJ: Resistance to EGFR-targeted therapy: a family affair. Cancer Cell, 2011; 20:423–425.
7.
CunninghamD, HumbletY, SienaS, KhayatD, BleibergH, SantoroA, BetsD, MueserM, HarstrickA, VerslypeC, ChauI, and Van CutsemE: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 2004; 22:337–345.
8.
KishiroY, KagawaM, NaitoI, and SadoY: A novel method of preparing rat-monoclonal antibody producing hybridomas by using rat medial iliac lymph node cells. Cell Struct Funct, 1995; 20:151–156.
9.
AsanoR, IkomaK, KawaguchiH, IshiyamaY, NakanishiT, UmetsuM, HayashiH, KatayoseY, UnnoM, KudoT, and KumagaiI: Application of the Fc fusion format to generate tag-free bi-specific diabodies. FEBS J, 2010; 277:477–487.
10.
MiyazakiJ, TakakiS, ArakiK, TashiroF, TominagaA, TakatsuK, and YamamuraK: Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5. Gene, 1989; 79:269–277.
11.
GillGN, KawamotoT, CochetC, LeA, SatoJD, MasuiH, McLeodC, and MendelsohnJ: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem, 1984; 259:7755–7760.
12.
BoulianneGL, HozumiN, and ShulmanMJ: Production of functional chimaeric mouse/human antibody. Nature, 1984; 312:643–646.
13.
JonesPT, DearPH, FooteJ, NeubergerMS, and WinterG: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature, 1986; 321:522–555.
14.
HackelBJ, NeilJR, WhiteFM, and WittrupKD: Epidermal growth factor receptor downregulation by small heterodimeric binding proteins. Protein Eng Des Sel, 2012; 25:47–57.
15.
RooversRC, VosjanMJ, LaeremansT, el KhoulatiR, de BruinRC, FergusonKM, VerkleijAJ, van DongenGA, and van Bergen en HenegouwenPM: A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer, 2011; 129:2013–2024.
16.
BoersmaYL, ChaoG, SteinerD, WittrupKD, and PlückthunA: Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem, 2011; 286:41273–41285.
